Home › Compare › IMPL vs RYLD

IMPL vs RYLD: Dividend Comparison 2026

IMPL yields 5000.00% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMPL wins by $62217131802825.30M in total portfolio value
10 years
IMPL
IMPL
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full IMPL calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — IMPL vs RYLD

📍 IMPL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMPLRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMPL + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IMPL pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMPL
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, IMPL beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMPL + RYLD for your $10,000?

IMPL: 50%RYLD: 50%
100% RYLD50/50100% IMPL
Portfolio after 10yr
$31108565901412.70M
Annual income
$29,930,990,143,689,105,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IMPL right now

IMPL
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-23.9
Piotroski
4/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMPL buys
0
RYLD buys
0
No recent congressional trades found for IMPL or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMPLRYLD
Forward yield5000.00% ✓12.39%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$62217131802825.35M ✓$45.3K
Annual income after 10y$59,861,980,287,378,210,000.00 ✓$2,682.98
Total dividends collected$62057786341622.61M ✓$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IMPL vs RYLD ($10,000, DRIP)

YearIMPL PortfolioIMPL Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$510,700$500,000.00$11,939$1,239.34+$498.8K → IMPL
2$24,410,935$23,864,485.98$14,158$1,382.89+$24.40M → IMPL
3$1,092,192,501$1,066,072,800.30$16,682$1,532.59+$1092.18M → IMPL
4$45,746,366,951$44,577,720,975.17$19,537$1,687.64+$45746.35M → IMPL
5$1,793,932,828,410$1,744,984,215,772.56$22,752$1,847.20+$1793932.81M → IMPL
6$65,871,973,805,320$63,952,465,678,921.49$26,355$2,010.43+$65871973.78M → IMPL
7$2,265,146,887,602,700$2,194,663,875,631,007.20$30,376$2,176.45+$2265146887.57M → IMPL
8$72,954,689,148,998,180$70,530,981,979,263,280.00$34,847$2,344.43+$72954689148.96M → IMPL
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$39,800$2,513.54+$2201076182660.85M → IMPL
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$45,269$2,682.98+$62217131802825.30M → IMPL

IMPL vs RYLD: Complete Analysis 2026

IMPL — Stock

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Full IMPL Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IMPL vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMPL vs SCHDIMPL vs JEPIIMPL vs OIMPL vs KOIMPL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.